Publication of Phase III Study Shows Positive Results for Diabetic Neuropathic Pain

The results of a 13-week study by Avanir Pharmaceuticals, published in the journal Pain Medicine, show efficacy and safety of AVP-923 for treatment of diabetic neuropathic pain. Currently also in study for multiple sclerosis, the combination of Dextromethorphan and Quinidine (AVP-923) showed its effectiveness in treating diabetic neuropathic pain, particularly a reduction in leg pain. READ MORE

Source: PR Newswire